Tulasigeri M Totiger
Overview
Explore the profile of Tulasigeri M Totiger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaudhry S, Beckedorff F, Jasdanwala S, Totiger T, Affer M, Lawal A, et al.
Leukemia
. 2024 Jul;
38(9):1894-1905.
PMID: 38997434
SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) revealed responders were enriched with SF3B1 mutations....
2.
Srinivasan S, Mehra S, Bianchi A, Singh S, Dosch A, Amirian H, et al.
bioRxiv
. 2024 Jun;
PMID: 38903082
Background And Aims: induction of alcoholic chronic pancreatitis (ACP) causes significant acinar damage, increased fibroinflammatory response, and heightened activation of cyclic response element binding protein 1 (CREB) when compared with...
3.
Chaudhry S, Castro J, Totiger T, Afaghani J, Khurshid R, Nicholls M, et al.
ACS Med Chem Lett
. 2024 Jun;
15(6):945-949.
PMID: 38894933
STK17A is a novel uncharacterized member of the death-associated protein family of serine and threonine kinases. Overexpression of STK17A is observed in many cancers. We identified a lead compound that...
4.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson M, Chirino A, et al.
Science
. 2024 Feb;
383(6682):eadi5798.
PMID: 38301010
Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies. Here we identify...
5.
Bewersdorf J, Stahl M, Taylor J, Mi X, Chandhok N, Watts J, et al.
Leukemia
. 2023 Oct;
37(12):2512-2516.
PMID: 37814121
No abstract available.
6.
Totiger T, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36831175
Therapeutic developments targeting acute myeloid leukemia (AML) have been in the pipeline for five decades and have recently resulted in the approval of multiple targeted therapies. However, there remains an...
7.
Totiger T, Chaudhry S, Musi E, Afaghani J, Montoya S, Owusu-Ansah F, et al.
J Cell Mol Med
. 2023 Feb;
27(4):587-590.
PMID: 36722323
XPO1 (Exportin-1) is the nuclear export protein responsible for the normal shuttling of several proteins and RNA species between the nucleocytoplasmic compartment of eukaryotic cells. XPO1 recognizes the nuclear export...
8.
Jahn J, Diamond B, Hsu J, Montoya S, Totiger T, Landgren O, et al.
Leuk Res
. 2023 Jan;
126:107020.
PMID: 36696829
Therapy-related myeloid neoplasms (t-MN) account for approximately 10-15% of all myeloid neoplasms and are associated with poor prognosis. Genomic characterization of t-MN to date has been limited in comparison to...
9.
Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Arango Ossa J, et al.
Blood
. 2023 Jan;
141(19):2359-2371.
PMID: 36626250
Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the...
10.
Nguyen N, Chaudhry S, Totiger T, Diaz R, Roberts E, Montoya S, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):73.
PMID: 36261486
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to...